000291417 001__ 291417
000291417 005__ 20241121142146.0
000291417 0247_ $$2doi$$a10.1038/s41416-024-02740-5
000291417 0247_ $$2pmid$$apmid:38942989
000291417 0247_ $$2ISSN$$a0007-0920
000291417 0247_ $$2ISSN$$a1532-1827
000291417 037__ $$aDKFZ-2024-01391
000291417 041__ $$aEnglish
000291417 082__ $$a610
000291417 1001_ $$0P:(DE-He78)96b8904da6b50cab64b4393f7b0672ce$$aSeiboldt, Till$$b0$$eFirst author$$udkfz
000291417 245__ $$aSynergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.
000291417 260__ $$aEdinburgh$$bNature Publ. Group$$c2024
000291417 3367_ $$2DRIVER$$aarticle
000291417 3367_ $$2DataCite$$aOutput Types/Journal article
000291417 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1725280336_17193
000291417 3367_ $$2BibTeX$$aARTICLE
000291417 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291417 3367_ $$00$$2EndNote$$aJournal Article
000291417 500__ $$a#EA:B310#LA:B310# / 2024 Sep;131(4):763-777
000291417 520__ $$aCertain paediatric nervous system malignancies have dismal prognoses. Retinoic acid (RA) is used in neuroblastoma treatment, and preclinical data indicate potential benefit in selected paediatric brain tumour entities. However, limited single-agent efficacy necessitates combination treatment approaches.We performed drug sensitivity profiling of 76 clinically relevant drugs in combination with RA in 16 models (including patient-derived tumouroids) of the most common paediatric nervous system tumours. Drug responses were assessed by viability assays, high-content imaging, and apoptosis assays and RA relevant pathways by RNAseq from treated models and patient samples obtained through the precision oncology programme INFORM (n = 2288). Immunoprecipitation detected BCL-2 family interactions, and zebrafish embryo xenografts were used for in vivo efficacy testing.Group 3 medulloblastoma (MBG3) and neuroblastoma models were highly sensitive to RA treatment. RA induced differentiation and regulated apoptotic genes. RNAseq analysis revealed high expression of BCL2L1 in MBG3 and BCL2 in neuroblastomas. Co-treatments with RA and BCL-2/XL inhibitor navitoclax synergistically decreased viability at clinically achievable concentrations. The combination of RA with navitoclax disrupted the binding of BIM to BCL-XL in MBG3 and to BCL-2 in neuroblastoma, inducing apoptosis in vitro and in vivo.RA treatment primes MBG3 and NB cells for apoptosis, triggered by navitoclax cotreatment.
000291417 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000291417 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291417 7001_ $$0P:(DE-He78)7cf43fe3da2429e80c087d85018b09e4$$aZeiser, Constantia$$b1$$udkfz
000291417 7001_ $$0P:(DE-He78)068f2a9a434bde6bdd0b039f6a7ee5d2$$aNguyen, Duy$$b2$$udkfz
000291417 7001_ $$0P:(DE-He78)32e22d1c8416af3f2a612da9121f2c05$$aCelikyürekli, Simay$$b3$$udkfz
000291417 7001_ $$0P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd$$aHerter, Sonja$$b4$$udkfz
000291417 7001_ $$0P:(DE-He78)f08873535c440e3ce033c84d5786f70f$$aNajafi, Sara$$b5$$udkfz
000291417 7001_ $$0P:(DE-He78)680b50042d6f35e6482a0c32a0913a56$$aStroh-Dege, Alexandra$$b6$$udkfz
000291417 7001_ $$aMeulenbroeks, Chris$$b7
000291417 7001_ $$0P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aMack, Norman$$b8$$udkfz
000291417 7001_ $$0P:(DE-He78)0554b5244334538d7a8afa2552a6d29c$$aSalem-Altintas, Rabia$$b9$$udkfz
000291417 7001_ $$0P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aWestermann, Frank$$b10$$udkfz
000291417 7001_ $$0P:(DE-He78)f2a782242acf94a3114d75c45dc75b37$$aSchlesner, Matthias$$b11$$udkfz
000291417 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b12$$udkfz
000291417 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b13$$udkfz
000291417 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b14$$udkfz
000291417 7001_ $$00000-0003-2650-586X$$aVogler, Meike$$b15
000291417 7001_ $$0P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aPeterziel, Heike$$b16$$udkfz
000291417 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b17$$udkfz
000291417 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b18$$eLast author$$udkfz
000291417 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-024-02740-5$$n4$$p763-777$$tBritish journal of cancer$$v131$$x0007-0920$$y2024
000291417 8564_ $$uhttps://inrepo02.dkfz.de/record/291417/files/s41416-024-02740-5.pdf
000291417 8564_ $$uhttps://inrepo02.dkfz.de/record/291417/files/s41416-024-02740-5.pdf?subformat=pdfa$$xpdfa
000291417 909CO $$ooai:inrepo02.dkfz.de:291417$$pVDB
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)96b8904da6b50cab64b4393f7b0672ce$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7cf43fe3da2429e80c087d85018b09e4$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)068f2a9a434bde6bdd0b039f6a7ee5d2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32e22d1c8416af3f2a612da9121f2c05$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f08873535c440e3ce033c84d5786f70f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)680b50042d6f35e6482a0c32a0913a56$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0554b5244334538d7a8afa2552a6d29c$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f2a782242acf94a3114d75c45dc75b37$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-2650-586X$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000291417 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000291417 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000291417 9141_ $$y2024
000291417 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-22$$wger
000291417 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2022$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000291417 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2022$$d2023-10-22
000291417 9202_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000291417 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000291417 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000291417 9201_ $$0I:(DE-He78)W610-20160331$$kW610$$lCore Facility Omics IT$$x2
000291417 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x3
000291417 9201_ $$0I:(DE-He78)B087-20160331$$kB087$$lB087 Neuroblastom Genomik$$x4
000291417 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x5
000291417 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x6
000291417 9200_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000291417 980__ $$ajournal
000291417 980__ $$aVDB
000291417 980__ $$aI:(DE-He78)B310-20160331
000291417 980__ $$aI:(DE-He78)HD01-20160331
000291417 980__ $$aI:(DE-He78)W610-20160331
000291417 980__ $$aI:(DE-He78)B062-20160331
000291417 980__ $$aI:(DE-He78)B087-20160331
000291417 980__ $$aI:(DE-He78)C060-20160331
000291417 980__ $$aI:(DE-He78)FM01-20160331
000291417 980__ $$aUNRESTRICTED